3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
47
Neoplasm Metastasis
9
Neoplasms
8
Prostatic Neoplasms
7
Brain Neoplasms
7
Endometrial Neoplasms
6
Glioblastoma
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Meningioma
3
Carcinoma, Renal Cell
3
Sarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Oligodendroglioma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Liposarcoma
2
Hematologic Neoplasms
2
Glioma
2
Breast Neoplasms, Male
2
Breast Diseases
2
Breast Cancer Female
2
Venous Thromboembolism
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Interventions
Fluorouracil
41
Radiotherapy
38
Cisplatin
35
Oxaliplatin
32
Leucovorin
24
Paclitaxel
22
Irinotecan
20
Docetaxel
17
Neoadjuvant Therapy
14
Carboplatin
13
Radiation
12
Capecitabine
12
Surgical Procedures, Operative
10
Cetuximab
8
Biopsy
8
durvalumab
7
Gefitinib
7
Chemotherapy, Adjuvant
7
tremelimumab
6
pembrolizumab
6
Nivolumab
6
Magnetic Resonance Spectroscopy
6
Folfox protocol
6
Taxes
5
Immunohistochemistry
5
Endoscopy
5
Gene Expression Profiling
4
Epirubicin
4
Drug Therapy
4
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma Of Esophagus
×
abemaciclib
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled